“Deucravacitinib in Moderate to Severe Plaque Psoriasis: 5-Year, Long-Term Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials”. SKIN The Journal of Cutaneous Medicine, vol. 9, no. 2, Mar. 2025, p. s532, https://doi.org/10.25251/skin.10.supp.532.